Bavaro et al. Remdesivir for COVID-19 LATE TREATMENT
Is late treatment with remdesivir beneficial for COVID-19?
Retrospective 331 patients in Italy (July 2021 - March 2022)
Lower severe cases with remdesivir (p=0.00099)
Bavaro et al., Viruses, doi:10.3390/v15051199
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study
Bavaro et al.
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in..
Retrospective 331 hospitalized COVID-19 patients in Italy, showing lower progression with remdesivir. Combination therapy with mAbs was more effective, and improved results were seen for immunocompromised patients.
[ Gérard, Wu, Zhou]
show significantly increased risk of acute kidney injury with remdesivir.
risk of severe case, , treatment 120, control 211, propensity score weighting.
7.0% lower, RR 0.93, p < 0.001
Effect extraction follows
pre-specified rules prioritizing more serious outcomes. Submit updates
Bavaro et al., 19 May 2023, retrospective, Italy, peer-reviewed, median age 75.0, 27 authors, study period 1 July, 2021 - 15 March, 2022.
email@example.com (corresponding author).
Efficacy of Remdesivir and Neutralizing Monoclonal
Antibodies in Monotherapy or Combination Therapy in
Reducing the Risk of Disease Progression in Elderly or
Immunocompromised Hosts Hospitalized for COVID-19:
A Single Center Retrospective Study
Davide Fiore Bavaro 1, * , Lucia Diella 1 , Alessandra Belati 1 , Giuliana Metrangolo 1 , Laura De Santis 1 ,
Vito Spada 1 , Michele Camporeale 1 , Angelo Dargenio 1 , Gaetano Brindicci 1 , Flavia Balena 1 ,
Deborah Fiordelisi 1 , Fabio Signorile 1 , Giacomo Loseto 2 , Crescenza Pasciolla 2 , Carla Minoia 2 ,
Immacolata Attolico 3 , Tommasina Perrone 3 , Simona Simone 4 , Maria Rendina 5 , Nicoletta Giovine 6 ,
Francesco Di Gennaro 1 , Pellegrino Musto 3,7 , Attilio Guarini 2 , Alfredo Di Leo 5 , Loreto Gesualdo 4 ,
Maria Dell’Aera 6 and Annalisa Saracino 1
Citation: Bavaro, D.F.; Diella, L.;
Belati, A.; Metrangolo, G.; De Santis,
L.; Spada, V.; Camporeale, M.;
Dargenio, A.; Brindicci, G.; Balena, F.;
et al. Efficacy of Remdesivir and
Neutralizing Monoclonal Antibodies
Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area,
University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy
Hematology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
Unit of Hematology and Stem Cell Transplantation, AOUC Policlinic, 70124 Bari, Italy
Nephrology Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and
Ionian Area, University of Bari, 70124 Bari, Italy
Section of Gastroenterology, Department of Emergency and Organ Transplantation, University of Bari,
70124 Bari, Italy
Hospital Pharmacy Department, University Hospital of Bari, 70124 Bari, Italy
Department of Precision and Regenerative Medicine and Ionian Area University of Bari and Unit of
Hematology and Stem Cell Transplantation, AOUC Policlinico, 70124 Bari, Italy
Correspondence: firstname.lastname@example.org; Tel.: +39-080-5594529; Fax: +39-080-5592301
in Monotherapy or Combination
Therapy in Reducing the Risk of
Disease Progression in Elderly or
Hospitalized for COVID-19: A Single
Center Retrospective Study. Viruses
2023, 15, 1199. https://doi.org/
Academic Editors: Karolina
Akinosoglou, George T. Dimopoulos
and Wei Xu
Received: 29 April 2023
Revised: 16 May 2023
Accepted: 17 May 2023
Published: 19 May 2023
Copyright: © 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
Abstract: Introduction: Remdesivir (REM) and monoclonal antibodies (mAbs) could alleviate severe
COVID-19 in at-risk outpatients. However, data on their use in hospitalized patients, particularly in
elderly or immunocompromised hosts, are lacking. Methods: All consecutive patients hospitalized
with COVID-19 at our unit from 1 July 2021 to 15 March 2022 were retrospectively enrolled. The
primary outcome was the progression to severe COVID-19 (P/F < 200). Descriptive statistics, a Cox
univariate–multivariate model, and an inverse probability treatment-weighted (IPTW) analysis were
performed. Results: Overall, 331 subjects were included; their median (q1–q3) age was 71 (51–80)
years, and they were males in 52% of the cases. Of them, 78 (23%) developed severe COVID-19.
All-cause in-hospital mortality was 14%; it was higher in those with disease progression (36% vs. 7%,
p < 0.001). REM and mAbs resulted in a 7% (95%CI = 3–11%) and 14% (95%CI = 3–25%) reduction in
the risk of severe..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
provide treatment protocols.